Document Z8yZ3NjDn68evqXg9ajJkNZ1O
$f
rIGINAL
marsorr | JRAE-0993 Sty Tie
Toxicokinetic Study ofPerfluorooctane Sulfonamide (PFOSA; T-7132. 2) in Rats
Authors
AnTdoxriecwolMo.gySeSapceactiaPlhis.tD. 3M Medical Department, Corporate Toxicology
Deanna J. Luebker M.S.
`Advanced Texicologist 3M Medical Department, Corporate Toxicology
Date: August 11, 2000
StepTsestTingaFactilitysrs
3M Center 270-38-05 Saint Paul, MN 55144
5 on
So
73M13S2m2ePgFOTSoxAicPoKlosguydSyTi3n9racs
Summary:
ePluirmpionsaet:ion kineTthiecsopufrpPoesrefloufortohiosctsatnuedySuwlafsontoamaisdsees(sPtFheOSreAl)atiivnetahbesroartpftioolnl,owmientgabaosliinsgml,e aornadl dose.
M80e,thasodtshe: vehicTlewcoongtroolu,psorofS fmigft/ekeng mPaFlOeSaAtsseuascphenrdeecdeiivned22%sTinwgelee ndo8s0eobfyeoirtahlegrav2a%ge.Tween Pwearsflfuoournodocttoabneoa9t6e %(PpOuArAe)Fwiaves rfaotusnfdroatmaealecvheldoosfe g2.r5 onugp/mwlerien tshaecrdiofsiciendgosnoldutaiyosn.1,T4h,eaPndOS29A. pproesstsduorsee.liLqiuivdercharnodmasetroagrwaeprheyaenlaelcytzreosspfroaryPtFaOnSduAmamnadsistssppreecdtircotmeedtmreyt(abHoPlLitCe/sEuSsMiSngMSh)ig,h-
Rpeesruflltuso:rooctaneTshuelfvoenhaitcele(PcFonOtSr)olingrliovuepr hoardsenrao. dTehteectPaFblOeSlAevedlosseofgProFuOpShAadordecreasing levels
sotfudPyF.OLSiAv,erwciotnhceevrirdaetnicoenosfofcoPnFveOrSsAioanvoefraPgFeOdS7A.0tpopPmF,O3.7Spipn mli,veranadnd0.s1erpaptmhroonugdhaoyust1,th4e, anc.
c2o6ncpeosntt-rdaotsieo,nsroefspePcFtiOvSelAy,awvietrhagaenda0p.p3arpepnmt lainvder0.h1elpf.pimfeoonfedlaiymsin|a2tinodn4opfos5t.2dodsayes.resSpeercutmi.vely,
easntdimwaetreed utondbeetelcetssabtlhearby4ddaayys.29Lipvosetr-PcoFsOe,Swciotnhceanntraaptpiaornesntwesreeru2m8.h2alpfp-lmi,fe3o7f.4elpipmimnaatnidon23.8
prepsmpe,ctrievperleys.enSteirnagP2F2.O0S%,av3e2r.a3g%e,da8n.d2 2pp5m.,2%8.o6ftphpem,PFanOdS4A.6dopspemd,oonnddaayyss1,1,44 aannddd2a9yp2o9stp-odsotse
dose liver
rweesrpeec3i5v.2e,ly4.1.1T,heanadve2r3a.g9eptpotmalocnondcaeynstr1a,t4i.onasndof2P9 FpOosSteedqousiev.alreesnptesct(iPveOlyS.
PFOSA) in The average
pcopnmceontnedataiyo4nspoofstPdFoOsSe aenqudidveaclernetasseidn 1t0he4.s6erpapi:ncorneadsaedy 2fr9opmos8t.5dopspe.mTohnedlaiyve|s ptoossterdaosPeFtO0S8.7
c2onndc2e9nupaotsitodnosraet,ioreisnpcercetaivseeldy.thTrootuaglhoPuFtOtSheesctuuldvaylweintths ivnaltureesloivfer a4.2.nd4.8s.eraandpe5a.k4eodr.odnadyasy1, 4,
ppopsmt dPoOseAaAt 3w5a.s4f%ouanndd i6.n0 %theosfetrahoenPdFaOyS| eaqnudivdaalyen4tspodsotseddo.ser,esapnedctievqeulayl.edAn31a.v2e%raagnedo2f40..11%of
the POA residual present in the dose, respectively
Cliovnecrlaunsdiosnesra: fPoelrlfolwuionrgooacnroarnaelsuelxpfoosnuarmei,dePwFaOsSrAeawdialsyparbosgorrebsesdivferlyommetthaebgoultizaendd tfooPunFdOSin,the
`liwvheirc,hraecpcreusmeunltaitnegd22in.t0h%e 3l2iv.e3r%asaenvdi2d5e.nc2e%dobfytthehePhFiOghScAondcoesnetdr,atoinondoafysP1F.4OSarddet2e9ctpeodstindotshee
rceasypse.ctTihveelyP.OTAhAe parpepsaernetntinhtahlelisevreaoofnedlaiymsina1 tainodn 4ofpPosFtO-dSoAseincotuhledlibveeracwcaosunatpepdrfoorxibymathtee5.l2y.
residual POAA in POAA was found
the cosing solution, in this study:
therefore.
no
direct
evidence
for
metabolismof
PFOSA
to
5
Page20f18
737M1S3a2t2egPiFcOTSoxAicPoKlosgtyudSyTi3n9ras
Introduction
`cTlheearoabnjceec,tiavnedobfiotlhoisgisctauldpyewrsaisstteonacseosefssPetrhfelpuootreonoticatlanfeosruolrfalonaabmsiodrept(iPonF,OuSrAi)nairny maanldefSecparlague
Dmeatwalboelyitreatss oafftPerFaOsSiAngwleasorpalerdfooser.meAdnablyysLiCsMoSf.theUrsienreumanadndfelcievserwefroce PalFsOo ScAollaencdtepdotaenndtimalay
bPereavniaoluyszsetdudbiyesLoCnMNS-eatnhdylppeerrhfalpusorootchtearnmeseutlhfoodnsamaisddee(e1)m,etdheneNc-ecstsahryy].derivative ofPFOSA,
c`mhirsotmaaketnolgyrcaopnhcylaundaeldyttihceatl PteFcOhnSiAquweausstehdeinultthiomsaetesmtuedtiaebsolwiatse uinnarbaltes (t1o,2d)e;tehcotwePvFeOrS,. thDeiegtaasry
administrationof N-ethylperfluoroctanesulfonamidoethanol (N-EXFOSE) inrats, and in-vitro
mPeFtOaSboAli(s3,m4b,yanhedpa5)t.ocFyutretsherersmuolrtes,prPiFmaOrSilAy hinsthbeeefnorimdaetnitoifnioedfaPsFapOoStewnittdhiaremctinuonrcoaumpoluenrtofof
`mitochondrial PFOS had not
respization in-vitro been demonstrated
(6). and
Prior to the the relative
ctuorxriecnotkisnteudiyc,sodfirePcFt OmSetAabwoelriesmuonfknPoFwnO.SA
0
PMFeOtaSo.disnwseerreumreacnendtllyivveraldiodawtned10fotrhethleoqwupaarritiptaetriobnilolfioPnFlOevSeA{ (a7)n.dIint-svpiovtoensttiuadliemsetwaebroel.itteh,us,
warranted to investigate the toxicokinetics of PFOSA.
Materials
TTnhiteiatlesatnamlaytseirsiablywGasCMidSentdieftieerdmaisnePdertfhlautotrhoe.ocstuarniensgumlaftoenraimaildewa(sPFoOveSrA)9;9%Loptunruem(b8)e.rQLu-al1i0t0a0t9i.ve
ainsodmqeurandtiisttartiibvuteicoonmwpaossiatpipornoaxlirmeastuletlsyd6e5r.iv8e%dCfFr3om(C'FH2a)nxd-*SFO2--NNMHR2a(nNaolyrsmiaslrechvaeianl)e,d 1th8a.t7t%he
rinetveeranlaeldmloonwo-lmeevtehlyi!mpburraintcihesaonfd
11.2% Isopropyl 9,600 ppm PFOS
branch (9). HPLC/MS characterization (0.96 %), and lower concentrationsof
several
o1tgh/emrla(m0i.d2e5s%(o1f0).thPeenrfolmuionraolosdtoasneo)at(1e2)(.PBOaAsAe)d woansthfeousrudmiorfthtehedoirsaipnugritsioelsu,titohne apturaiteyveolf tohfe.2.5
PFOSA sample was determined to be approximately 96% (8,9 & 10).
Methods
The protocol (11) and analytical methods (12) used in thi study ave briefly described below. Dose and Dosing Procedures:
rAatssi(nogblteaSimnegd/kfgrodmosHearolfaPn FLaObSorAatwoarsieasd)mionnidsateyrzeedrovoiafotrhael
gavage study.
to 15 male Sprague Dawley The PFOSA was preparaesd
a
w1e%ig(h1tmwga/smla)dmuinniifsotrermesdutsopecnascihonrati.n 2Th%eTvweehiecnle80c.ontArovloglruomuep,ocfo$nsmiistsiunsgpoefns1i5omne/lkegSbpordaygue
Dawley rats at2 volume
o(aflSsomioibktaginoenddfaryozmerHoaorfltahneLasbtourdayt.ories),
received
29%
Tween
80
in
deionized
water
Page3of18
T37M1S5t2atgPiFcOTSoxAicPoKlosguydSyTn39as
Specimen Collection:
osUanrcirdniaefyiascne1do, n4f,edcaaenysd2c2o9l9pleopcoststitodndososseweegrraoenudpm.gardFoeisvs0e3naedncairymosapls1sy~wf4arsopmopscetarcfdohorsdmeoedsf.erogmrSoetuhrpeaawnnedirmelaielvuesrtdhwaeensriiezgeacdotlebldyucfCtoOerd; from cach animal and flash-frozen in liquid nitrogen. Specimen Handling:
wPSepAreDec,iamn3eanlMsyzE(enudrviibnryeo,3nfmMeecneEtsn,avlliirTveoernc,mhaennnotdlaoslgeyfrouarmn)tdhweSeaprafereermnatSiecnrtovamiicpneoesdu, nfadtor-aa7nn0dalmCyestiasan.bdoLlsiievtneetsr.tao nTKdisserHaasnasmepnl,es ffdooerrtePpcotOsisoSinbl(weeLfrOuetDu8)r.e4f5aonrnagPlyiFsmiOlsSiaAnslawipevperrreopar3ni.da5t1ne..g7/4mnigi/nmtiheinlitvheersaenrda 1(1.25),ngU/rminleianntdhefescereahs.ewTelhriemeitLrseOroDafisned Results
Control Groups:
Body and Liver Weigh
TiTohhedesaneavr&earpsaogsletosidtnoiastniea,lavtbheeroadagyveewrofeagieg2hb.2 ogxdybSoDwdoeyfigtwhehtiegghfatiinfriwoeanmsvde2ha4iy.c2zleercoaontnodtodrlaoymma1 ldpeaoysrtaztdsearswoea.1s0 2F7r3o.m7 2da7y.3z6r0
wdoesieg.htbopderycweentiagghetsianrceresahsoedwnanianvTearbalgee
of 114.1 14,
g.
Liver
weights
and
relative
day liver t
29 pose body
CLiovnetroalnadnSiemraalsCohnacdenntoradetcieocntsable this study (data rot shown).
levels
of
PFOSA
or
PFOS
in
liver
or
sera
at
any
timeduring
PFOSA Dose Groups:
Bods and Liver Weight
TiTphhedesaaeyvre4artpasogsLetosidtnoiastniea,lavtbheoerdaaygveewreoafi4gg.eht5bg=ocSbyoDwodefyitgwhheteiggfhaitifntferwenoamsPdF2a0Oy.S0zAerdonodseddframoyaml|edpaorysattsdwosaes. 27F0r.o0m%d3a.6y ecoro
woesieg.htbopderycweentiagghetsiwncerreeaseeqduiavnalaevnetratogecoonftr1o0l0v9algu.esLi(vTearblweei1g8h)ts
and
zero relative
to dey liver 10
29 post boy,
iver and Sera Concentrations
PanRdOsSerAaalnedvePlsRoOfSPwFeOrSeAdewteercetehdiignhetsht alinvedrayan|dpsoestaodfosaellaanndidmraolsppdeodsesdigwniiftihcaPnFtOlySbAe.twLeievner
:
Page dof 18
: 3T-M71S5m2a2ugPiFcOTSoAxicPoKlosgyySTi3n9ras
fdiavyesr c1oanncden4trpaotsitondsosoef aPnFdOaSgAaidnebcreetawseeednfdraoyms a4papnrdox2i9maptoesltydo7s.e0 (pTpamblteos32.7anpdp3)m. tTohe0.a1veprpagme
ifnrothmedlaiyvser1w1a0s4,ca1l0cu2l9atpeodstfrdoosme,a lroegspleicnteiavrelryeg(rTeasbslieon2o).ftThheelhiavlefr-lPifFeOoSfAelciomnicneanttiroantoifonPsFtOoSbAe.
n5g2/mdla)yso.n Tdhayesse1,ra4,coanncden2t9raptoisotndsoosfe,PrFeOspSeActiwveerley 0(.T3ab%le0.31).pTphme, h0a.l1f-li0f.0e ofzenldim<iLnaOtDio(n1.o7f4
APvFeOzSagAeiPnFtOheSlsievreurmancadnnsoetrableevceallscupleaatkeeddfroonmdtaisy4daptoas,t bduotseisaensdtidmeactleidnetdo bbye dleasys2t9hapnos4tddayoss.e
ftorolmow2e8r.2l.e2ve6l.s1tphapnmfoonunddayon1 dpaoystondeo.seAv(e0r3a7.g4 e=2 3S.D6 plipvemr oPnFOdaSyl4evpeolsstidnocsree.aseLdevseilgsnitfhiecanntly
dveaclrueesasweedresiagnpipfriocxanitmlayte10ly23$.8pp=m4.o1npdpamy
by day 29 1 and day
post dose (Table 4 post dose, ther,
2). Average sera PFOS decreased significantly to
approximately 4.6 ppm on day 29 post dose (Table 3).
ver and Sera Concentrations as a Percentage of Dose
dTohseepaetr$ce.n4t%agaendof0P.F2O%SrAespdeocstievdeldye.tecBtyeddaasy P4FpOosS:Adoisne.thethleisveerleavnedlssehraadpderaokpepdedontoda3y.2o%neanpdost 00.00%%(aTnadblbey6d).ay 29 post dose the liver levels dropped 10 0.1 % and the sera levels remained at
#Theonpedracyen1tpPosFtOdSoseequainvdaliennctrsedaossededt0de3t2e.c3te%daansdP6F.O0S% biyn tdhaeyli4veprosatnddossee.re wOansd2a2y.209%paonsdt d5o.s2e,
these could
laecvceolsunhsadfodrro3p5p%e,d2t.o5%2.5.a2n%d
a5n.d6%4.o1f%,threePspFeOctSivfeoluyn(dTaibnlseer6a),.
Residual and 3.6%,
PFOS 2.7%,
in the dose and 3.9 %
of the PFOS found in liver on days 1,4, and 29 post dose, respectively (Tables 4 and 5).
p"Tohasetnpddeors5cee3ntt%hePseFdOlaeSyvee|lqsupdioevscatlrdeeonastseseddaon1s0de2id5n.cd4reie%cacsteaedaddtoa4s.315P.F%4O%iSn aetqnhudeivl6ia.vl0ee%rnatsnbdyinsdetarhyae4rleipvsoepsretcatdniodvseesl.eyr(aOTwnaabdlsae2y67)2.29 Sera POAA Concentrations
osPnaemrdfpallyuesosr1oionactnthdaen&cPapFtoeOstS(-APdOodsAoeAsr)eesgwpraeocstuipfveocluoyn.ndtaTaihtneaesdleePvveOallAsoAefsaet2q.5 aunvagle/rm3aig0e.i8nv%atlhaueneddsoo2si3fn.g50.1s%oalnruedtsip0oe.nc8t(i1pv2ep)l.my,SPeOraAA
POAA dosed (Table 7).
ofthe
Conclusions:
Nraoticosoumnpdoeurntdreraetlmaetnedt ecfofnedcittsiownesr.e observed on body weighs. iver weight, or liver/body weight
BfooltlhowPiFngOSanAoarnalddPosFeO. SAwpeprreoxfiomuantdealtyh3ig8h%ocfontcheentPatFiOoSnsAidnotsheedlwivaesr caonndvseerctaedoftoraPtsFoOnSe fdoayu.r
Page sof 18
T3-M71S3a2t2egPiFcOTSoxAicPoKlosgtyudSyTi3n9ras
PodfaFyaOspSpprowsoatxs-idmofasoteue.nldyPiR5.2nOtShdeAaylsli,evveaeralnsndddaimsmeiurncaihsahseahdlolrittneirbmoertephsoisidenertnascaetnhpadenrlwiivoeedrreionpvrteehrestesinemtrea,i.nwtSihiteghndiaofsiiecv,aenrtthlheyarlemff-oolrriefee
nPmoeFttOadbSeotAleirtcmoicnPoenOdv.AerANsoiwoagnsluofcfouPuronFndOiSidneAtohtriosoPtsthFueOdryS.cooTncjhcueugrarrtoeeudst.eowNeforeedliiarmneiacntlayetzvieioddneofnofrc,ePafFnodOr SmfueArttaihnbeorthliiinssvsemtsotuidfgyawtiaosn
wofaspoeslsiimbilneactoendjtuhgraotuegshinthteheluunrginveiaanedxpfiercaetsioins,wbaurtratnhtiesdh.asIt nsotpboseseinbldeettehratmisnoemd.eoTfhtehperePsRenOtSA
rreessuullttsinsguPggFeOstS
that the PFOSA is accumulated
from in the
the dose liver.
is
progressively
converted
to
PFOS
and
that
the
Page sor 18
3T7M15S2e.a2egPiFeOTSoxAicPoKlsoagydSyTmI9rt
Report Prepared by:
Signatures
Deanna Luebker, M Advanced Research Toxicologist
Andrew M. Seacat, Ph.D.
Toxicology Specialist
) Lac?
Report Reviewed by:
Fon 2. Bieatray JSeonhinorL. LBaubtoernahtoofrfy,MPahn.zDg.,erDABT, CIH
{ 200
Date
oif1e]for
Date
26 TH of
Date
Page of 18 10
T37M1S32m2ePgROTSoAxicPoKlorguydSyTnI9as
References:
J. rGaantrso.esvMsa.lmSua.antiTMohneRs.oifsd,iasnUtdnriiBvbo.uwtoiefonnG.eJoeMrlg.iimai(n,1a9At9ti0oh)ne,nTsia,snsdGuApe.oatne(analtlyissaoilspfooosfrsfilbbuilooyraicpncuabutlmeiudslhasetudiloafnso: nnGamroiordasleslympeaesntxipfcoiadsree:kd pR.estaincdidBeoinwceatns. JF.Mu.n(d1a9m9.0)ATppils.suTeodxiicsotlr,ibubtuitonnoatndfoeulnidm)inationof a fluorinated sulfonamide
2
aGnrdosasfmeranprMoRlo.ngMeidsdpiaegtealr,y eMxEpo.suarned Food Chem, 40, 2505 - 2509.
tBooawheinghLlMy.Au(o1r9i9n2a)teDdissturlifbountaimonidaendpetsitsiscuiedein
Jr.aAtsgrdiucr.ing
3. L6M2uC9lM2v,Sa/TnM-a6SD2..9E3.A,nTaanl-yd6t2Hi9ce4anliaoRnendpoJT.r-t61:9299965.6AbQyDuaErlaMittOaa1ntidv3ehMui,nmvaAednstvhiaegnapctaietoodncyBotifeotashnueasliiynnt-givciiatolrnoSsmeprervtiaacybeoLsl,CiAnsMcmoSfaTn-d
43pp.
4. S2Penomdoin-Tq-Gu6aK2n,9t4iLtfeotrwiovemesraa.ntaal1ny9ds9i8sh.uomfAdaTdn-i6th2ie9opn5aatliocCyrhtaatersaacnbtdyerhTiuuzrmabtaoinolnohoenfpSampterotacayybtLoelCsi/tiMensScoubafantdTe-dL62Ow9iM2t,hSAT1-.S66,226923, BTi-o6a2n9a3lytaincdalT-S6er2v9i4cebsy, LInOc.MS69/pMp.S. Analytical Report: 96AGKPO1.3M, Advanced
$: SPeearcfaltuoArMoo,ctaTnheosmslffoorndamiPdJo.EHthaannsoelnTKo.Jx.icainydiBnuRteesn.ho(fifn pJ.rLe.paSruatbi-oCnh,ro8n/i1e1D/i20e0t0a)ryN-Eibyl 6 UDWnlaiolvelenarecsreigteKyd.Bio.sf MoafrnNdatSStciahvroekosolmvoifAt.oMceh1do9i9nc8d,irnieTa..heDDueepfltfu.etcoht,foMfBNipeorc5fh5le8um1oi2rsi,tnraUtySeAad.nadrSyMulopalpteokcryutllesadurlbfByoinoaalmgoigodyue,ss ofnrom
3M Company
7.
CKhJa.raHcatnersiezna,tiLo.An.ofClOergmaenni,cMFEl.uotEolclhefesmoinc,alHsO.in Environmental Lab, S. Paul, MN $5133
JGoehnnesroanl.
P(o1p9u9l9a)tioCnoHmapmoaunndSeSrpaecSiafmipcles.
3M
8 PRaeypfoerrt R9/M2.4/9G9.C/5MMSSanAalCysiLsaobfBPuiFlOdSiAng(2L3-61-0200B9.)1.1 SAC Analytical Request No. 59426. 9. /TSpSoeMmcMtDrK-eos2stc3no6epr-y.2R8Ce-hqe1um1eis,ctasSle#pCt5he9a4mr2ab6ce.trer32i5Mz,atS1ip9oe9nc.ioafltPyFAOdShAe,siLv-e1s0&009C,hebmyic1aHlsanAdna1ly9tFi-caNlMLRaboratory 10. 2RD0ee1qR1uo-eo2ss9t,sF.CLA.-A1CT5h1Ca2r5a-4c.CtehrrRioezmapatotirootngs1oa0fp7Ph9Fy9O.GSrCAoourSppaomrpalteesA,naTl-y7t1i3c2a-]1T(eLc-h1n0o0l0o9g)y aCnedntTeNr-,AB-u1i5l8d4i.ng
Page Bof 18
n
377M1S3t2ra2tegPiFcOTSoxAicPoKlosgrydSyTi3n9ars. 11. SOeFacPaEt O&SLAucIbNkeRrA.TSP.rot3ocMolMoedricSatludDyeNpoa.rmTe-n7t15,2.C2o;rpSoTr-a3t9e,TPoxHiAcoRloMgAy.COOKctIoNbeErTI19C99.STUDY 12. LinabRoartast(oSreyrRaeaponrdt:LivAenra)l.ytLiacbaolraRtoerypRoeofpoDrratttNao.forFPACFTO-STAO(XT--1714352.(2W)28P1h4a)r.macToesktiinnegtic Study
LLaabboorraattoorryy,3FlMuoErnivnierAonnamleynttiaclalTCehcehmniosltorgyyT&eaSma.feLraybSoerravtiocreys,Co3ntMacEtn:viKrroinsmHeanntsaeln, Ph.D. 13. Alman and Dittmer, Blood and Other Body Fluids. FASEB, 1971, ps
2
Page9ofis
721M3S2t.at2egPiFcOTSoxAicPoKlosgydSTi3n9ras
Listof Tables: Table 1: Biological Parameters
1A: Control Group 1B: PFOSA Dose Group. Table 2: Liver PFOSA and metabolites in the PFOSA Group. Table 3: Serum PFOSA and metabolites in the PFOSA Group Table 4: Percent Dose: Liver PFOS equivalents in PFOSA Group. Tabl5e: Percent Dose: Serum PFOS equivaleats in PFOSA Group Table 6: Summary: Percent of dose in sera and liver. Table 7: Serum POAA in the PFOSA Group.
3
Page 100f 18
371M5S2r.a2tgPicFOTSoxAicPoKlosgiydSyTi2n9ras
[Fable 1A: Biological Parameters. Control Group
[Time Dose [anima#|l nial|Terminal|BW Gain] Liver [Liverwias
19R03-xxx| BW (g) | BW (g
[[DDayay 11_ CCoonnttrrooll O23301] g2r8a2i5l] p26e2n0al
a) | wi(g) | %ofBW
Dr5l i1r2a0] aa3s%l)
[Day 1_[Control
232 2774] 233 27417
2773] 2748]
031 124] a5 07] 118 42%
[Day1[ConTtrol 2342676, 2605] Java TT [Taran _aras
73] Tio, au 22 is] as
[[ Pay5a TC0ontrT ol| 2357 ] 2666] 21 884s3] 325 7a6] o16s]6 0351%4]
[Day 4_ [Control
236 275.8]
[Day a IContol 5572619]
301.8]
2834
260 114
a15 118
3.8%)
aay]
[7 D[Daayv@e CoCnotnrvoel|| 223380]]
2678950] 3a0szti72]
223287 i07a 3377%]
_--|
[56 [Day 28 [Control
TT" 3 [240] 2735
[Day 29 [Sonar 2412705
80
33870158]
247 oa o2u
11808.0301 114348]] 33.87%%]
[D[baayy2255[G[oCnotnrtorre [Gay 29 [Control
242 243
2802] 289.9
S654 asd
002 154.1]
Ted] 175
36% 39%)
204] 2663 3652 069 a3 35%
[lava TT [Iso
T2761] 380.00 32 314
waa] tas 230 15
saul 0.1%)
"
Pa11gofe18
PayT Smokal [PayTSmaka
2e5T 2632" 246] 664
7578]_ 2552
5a 68
704 102
-- sow au
Dart Ismael 248 2672 [PayTISmaka[peo 26871
2640 s6e3]
32 10.4] aa tor
36%) 40%]
E [ls T avo aT 7 T 6 20 2361a56 1asgt0o3s5 0so%w
[PaysTSmaka [Days Tsmaka
250" 666] 261 272i
2863 25a]
Ter 113 pas] tial
au ow]
[Day& TSmaka [Pay Smakal
250 2717 _2sas 253 2716] asta]
2a0l a1 ros 113
arm ao
[Paya TSmama ava |
ose pro Trio
assess 2510 200
tio 116
atm 40%
Par28 Smog] 256 2736 [Pay28Tsmaka[257 271.4"
380.3 1067 tad 5738] f025 a9
35%) 37%
[-- PaysSamvoakal72T8ar2e66s7
as57 srs
sao Tar fo0s fas
aw su]
L077 26 ws a7 15 ow
-
/
B SegR TooE S139
eb Ce POST a rrerbore T Tor PROS os
iomRaosl-{tiver pros) | Juver prose iver pros ros
E[eToimemmea m tm Txw xx ppe m er ppm e -- leq ppm"--
Briar
nC ----
-- e se a p r =
------ ------
BBbPaoreliofms mmere [a w we o y 3
Pomr e y ----] ----
BPE o aElpT mr ms T p e -- r s e Eo --ty 1i--] ---- ---- 3 Passeer s--T --)e -- e i--r ti--------m-------- ----1--2] e T==rSoinnimiccsaeTroeaaftrueenSrTroPommFdOooSaReFviSvoe SeseByyosa ns TrSaFrPoReOoSenP)ROS rd er rroms oi POGL= amecnoed saeuaasmoinoimoiraivvr t(rPal= 5paon 1E820)
Page 130018
CC
TMImSeBrOTSoxAicPoRlogytysTmIts
Table 3: Serum PFOSA and metabolites in the PFOSA Group .
7--_R--03: [sera FOS) [sera ROSA)
Time
xxx
ppm
ppm
SeFr7a0P8rOcaSA
ppm'
PadlpTs me egre T I w T r o s T s s
Ree bor
[avm3 c Ts woesrea y x]
PPDauoveimTso[ wemmeerss [ m To a a T r i on e l T ----] s --nd
[BpooisTBeoT mT emewesg Ta as s 7sT T o o e ms ----r ------u04g]]
Rseear fe
o4e]]
BoiTror Po
fmrmeoamnse-- T -- --aT se a --i solca s goonp-- --o ----------
[RuefdsIJsE mmeerkesT 1m mae a3rT -- g] opg
(M FFo Em--e-- 1f1eT e T--Ts s S5--|1r s -- --] ------]
[[| AsPsAucmRnintgenOt3r1aSitonatoo PFOSA PFO squmatenss ST PR--OSA--FFO--S ca--pmm1ss --3r--f
=MO=Lssi=gcnmiaectnantnotydyedetearceteannn fifomom:rs(cyaPyR18vOva=laSutes4s75boyry a2mwwooPtRaeOasSdATT~oas3eet5t0(epr<e0d.n0:050))
Lo=iDri of setcton (PROS = 1.76 nym: BFOSA S182 a
Page 140118
7ssFREFE REESE iEx sEaR ssEy HE :
gH
| EE
HE eb L L EEE 3 FEeEaaeEy FEEERE FRET
AH
ded LLL He 5of5}PEFRR REFERERNE R LH FFARRHEceHdEe:
E3 H d] INE
$
|
H{
(rl
| IT] [1 Ese
1111 [gist
5
J 53
FERREEEceRe BAaERaREaREEcet:ec EFEiRseEa| EeTEerlEi2i5Hi5i%
|
|
FT Esse
unin Ht [Rae -
=
3:2
fBrEEeRRsEAaEsNRcEeEsEA3A n5a3RsSEAREYRN EErEsBsamS umene nn|Ei 1
FreRee fad iesniEd
gad TTT TTTng BE
EcireSszR ERR R NhR
FFE
RR
RRR
i
SR Leg
52E 25 |E | |||]| FF[H HFERRh
[I11] IIT]g([ge%ag5sasg3eEs8d
|
Ili]
I Jsizs8g
H JEHR
LEE]
FTETT
[gssds
ig #i008
zaA gelzsle!| |la$B8a2eE2d8E||R1s|||
lool ||| (EggRglEslRs |ESly
| ||
[E288 [HFEREE
it ie Jr [|][foie||| Fae || Fis
/8
iii HLAERARRA i . SekSulEE RRE E E TIRES ESJEeleR21I33EEFT 35
Ess
f=iiiieds
STEaRenRTET
I rit
see
al
RI r
[1]!HlSll1 hi:
iii sad
=
:
fin
5 [1
R
BmhETEinanhS22EE 5[E1e 1R]|
PR 1
iiift
2
iSXsEFR8LEE
FHnERE
|
REERE
|T]REE ifsst
r i5z: [1 eil
Hl
H
e FFE a rN
HE
I
hh
FERTir,k ee| lB38]E:8
:
ffS2Ee5I
TERT|
FLFLEL |H]
Fa]
FTREEERFLl TERRER EJF R
RirTlEE
I
||]
i
GH
z F[1] ERREBil"iFrEel|leReE EEr HELaEoRREESTLTlSLelFB[eLHa2Ees8s
asiist
oe
EEeeEr[RReR1Ea]frR| eRTH FERrEEEeT aaeEEEheRE isHfEERE ALl |T || FfHiisli
H53E55 ! T TT
clisk FRET EE
prsiiE seis
2 iets FFFITART R [E RRRe i FRSERl S Ti5s25h2
i
i:
{EiEth
ffi e:
F [ETT e Ld n
ily
si
El
RE aFRE
TELp
o dl]ESHEET AEI [iiestss
= if] 2l3l1] |
TJ
E Liias
1Eis
"
3 FEE
3E] ENE=EE13
s|
Pl Iz
Elz
3:]
5MSs sEEJf E2<
s (f1 g ||
|
cs Pa IE2 |
glz
iz 5sa[igy] [g 583]
2 2$22 deTeyl B9fg ela]| Bg3E/z3S]
35 jeg [MER 5
20
HITT He Zs i i 5] B
F I$32i 38s %2 ilHENNF E E nN
<
i
HE
BEERS
=[=12(3I2
:
H2 I. SEE=E3ENEESEE
S5E le 2:g]
i5]i! E331 B k '
iil
gHE EiEf
2S:E :g
:i
|
HEEH]
3%
i
<
o
iit
zz
553
SHE2EF
21
